Chlorpromazine hydrochloride (DrugBank: Chlorpromazine)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 254 | ポルフィリン症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02943213 (ClinicalTrials.gov) | November 2016 | 21/10/2016 | Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride | A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions | Anti-Psychotic;Management of Manifestations of Psychotic Disorders;Treatment of Schizophrenia;Control Nausea and Vomiting;Relief of Restlessness and Apprehension Before Surgery;Acute Intermittent Porphyria;Adjunct in the Treatment of Tetanus;Control Manifestations of the Manic Type of Mani-depressive Illness;Relief of Intractable Hiccups | Drug: Chlorpromazine Hydrochloride | Cycle Pharmaceuticals Ltd. | Parexel | Completed | 18 Years | 65 Years | All | 20 | Phase 1 | South Africa |